ElevateBio has unveiled preclinical data for LETI-101, a CRISPR-based therapy for Huntington’s Disease (HD) being developed by its subsidiary, Life Edit. The therapy utilizes an AAV5 vector to deliver a CRISPR nuclease targeting a specific single nucleotide polymorphism (SNP) in the huntingtin gene (HTT) responsible for HD. Preclinical studies show LETI-101 successfully reduced mutant HTT protein levels by over 80% while preserving healthy HTT, a crucial aspect for maintaining normal cellular function.
This development is a significant advancement in the pursuit of effective HD treatments. Current HD therapies primarily address symptoms, not the underlying genetic cause. LETI-101’s targeted approach offers the potential to modify the disease course and significantly improve patient outcomes by addressing the root cause of the disease. This precision also minimizes the risk of off-target effects that could arise from less specific gene editing approaches. The positive preclinical data, coupled with regulatory guidance from the UK’s MHRA, increases the likelihood of LETI-101 progressing to clinical trials and eventually becoming a viable treatment option for HD patients.
In preclinical mouse models of HD, LETI-101 demonstrated a dose-dependent reduction of mutant HTT protein in critical brain regions affected by the disease. Studies in non-human primates confirmed the therapy’s safety profile and showed a promising biodistribution of the CRISPR system within the central nervous system, indicating effective delivery to target areas. Furthermore, the company has received positive regulatory feedback from the UK’s MHRA regarding the CMC and development pathway, which streamlines the process towards clinical trials.
The promising preclinical results and regulatory alignment position LETI-101 as a strong candidate for further development. ElevateBio’s integrated approach, combining gene editing technology, manufacturing capabilities, and therapeutic development expertise, suggests the potential for accelerated progress toward clinical trials. This development marks a crucial step towards a potential disease-modifying therapy for HD, offering hope for a future where this devastating disease can be effectively treated.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
